Pulmatrix PULM 深 沪
已收盘 12-12 16:00:00 美东时间
4.58
+0.620
+15.66%
华盛通- 最 高4.80
- 今 开4.05
- 成交量 3.56万股
- 最 低 4.05
- 昨 收 3.96
- 总市值 1672.75万
- 52周最高 10.40
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.9001
- 委 比 -99.70%
- 总股本 365.23万
- 历史最高 4235.00
- 量 比 2.69
- 振 幅 18.94%
- 历史最低 1.55
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
Pulmonx Corporation announced the reappointment of Glen French as President and CEO, effective immediately, and the appointment of Derrick Sung as COO and CFO, effective November 3, 2025. Steve Williamson and Mehul Joshi have resigned from their roles to pursue other opportunities. Preliminary, unaudited third-quarter 2025 revenue is expected to be approximately $21.5 million. The company has rescheduled the release of its third-quarter financial...
10-27 20:05
Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule drugs to the
10-16 20:17
Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.24) per share. This is a 66.2 percent increase over losses of $(0.71) per share from the same period last year.
10-16 20:14
Pulmatrix GAAP EPS of -$0.24
Pulmatrix press release (NASDAQ:PULM): Q3 GAAP EPS of -$0.24. The Company's total cash and cash equivalents balance as of September 30, 2025, was $4.8 million. The Company anticipates that its cash po...
10-16 20:13
Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.42) per share. This is a 73.58 percent increase over losses of $(1.59) per share from the same period last year.
08-06 20:16
Pulmatrix GAAP EPS of -$0.42
Pulmatrix press release (NASDAQ:PULM): Q2 GAAP EPS of -$0.42. The Company's total cash and cash equivalents balance as of June 30, 2025, was $5.8 million. The Company anticipates that its cash positio...
08-06 20:16
Pulmatrix Seeks Divestment Of Clinical Assets And iSPERSE Inhalation Technology Amid Advancements In Migraine, COPD, And Antifungal Treatments
Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ TechnologyiSPERSE™ TechnologyiSPERSE™ particles are engineered with a small, dense and dispersible profile to exceed
08-06 20:15
Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference
Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive lung disease treatments, announced it will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025. The presentation will be available live and archived on the company’s investor website. Pulmonx develops innovative devices like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System to treat severe emphysema/COPD. The Zeph...
07-29 20:05
Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
Pulmonx Corporation announced on July 16, 2025, that it will release its second-quarter 2025 financial results after market close on July 30, 2025. A conference call to discuss the results will follow at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Pulmonx investor website. Pulmonx is a global leader in minimally invasive lung disease treatments, offering products like the Zephyr® Endobronchial Valve for emphy...
07-16 20:05
Pulmatrix Stockholders Approve Merger with Cullgen
Pulmatrix ( ($PULM) ) has issued an update. On June 16, 2025, Pulmatrix held a ...
06-17 04:53
